What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Chemotherapy, Surgery, Oncology and Cancer.
In general Internal medicine, his work in Metastatic Urothelial Carcinoma, Clinical trial and Atezolizumab is often linked to In patient linking many areas of study.
As part of the same scientific family, Dean F. Bajorin usually focuses on Chemotherapy, concentrating on Survival analysis and intersecting with Docetaxel, Gastroenterology and Vincristine.
Dean F. Bajorin has researched Surgery in several fields, including Carcinoma and Urology.
His Oncology study combines topics in areas such as Germline mutation, Lynch syndrome, Targeted therapy, Toxicity and Immunotherapy.
Dean F. Bajorin works on Cancer which deals in particular with Bladder cancer.
His most cited work include:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial (1967 citations)
- Comprehensive molecular characterization of urothelial bladder carcinoma (1756 citations)
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (1345 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Chemotherapy, Surgery and Bladder cancer.
His Cisplatin, Cancer, Germ cell tumors and Metastatic Urothelial Carcinoma study in the realm of Internal medicine connects with subjects such as In patient.
His work in Oncology addresses subjects such as Pembrolizumab, which are connected to disciplines such as Vinflunine and Docetaxel.
His Chemotherapy study frequently links to related topics such as Urology.
The study incorporates disciplines such as Transitional cell carcinoma and Carcinoma in addition to Surgery.
His work deals with themes such as Cancer research and Clinical trial, which intersect with Bladder cancer.
He most often published in these fields:
- Internal medicine (66.57%)
- Oncology (57.46%)
- Chemotherapy (40.60%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.57%)
- Oncology (57.46%)
- Bladder cancer (31.34%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Bladder cancer, Cancer research and Metastatic Urothelial Carcinoma.
His research integrates issues of Germ cell tumors, Chemotherapy, Cisplatin and Cohort in his study of Oncology.
His Chemotherapy research incorporates themes from Muscle invasive and Urology.
His Bladder cancer study incorporates themes from Neoadjuvant therapy, Clinical trial and Bacillus.
In his research, DNA damage is intimately related to Gene, which falls under the overarching field of Cancer research.
His studies deal with areas such as Gastroenterology, PD-L1, Biomarker and Clinical endpoint as well as Metastatic Urothelial Carcinoma.
Between 2018 and 2021, his most popular works were:
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer (121 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Dean F. Bajorin mostly deals with Internal medicine, Oncology, Bladder cancer, Pembrolizumab and Chemotherapy.
His research in Internal medicine focuses on subjects like Gastroenterology, which are connected to Antibody.
His Oncology research includes themes of Survival rate, Cancer, Lynch syndrome and Cohort.
Dean F. Bajorin has included themes like Improved survival and Histology in his Cancer study.
His study in Bladder cancer is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Clinical trial and Dissection.
He interconnects Cystectomy and Urology in the investigation of issues within Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
